权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

利用靶向 IL-2 来减少免疫病理并增强对呼吸道病毒感染的免疫力

基本信息

批准号：
10334690
负责人：
Tara Marlene Strutt
金额：
$ 38万
依托单位：
UNIVERSITY OF CENTRAL FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10334690
关键词：
Adjuvant Adult Respiratory Distress Syndrome Advanced Development Affinity Animals Antibody Formation Antiviral Agents B-Lymphocytes CD8-Positive T-Lymphocytes Cells Clinical Development Disease Dose FOXP3 gene Generations Goals Hospitalization IL2RA gene Immune Immunity Immunoglobulin Class Switching Immunologic Memory Individual Infection Inflammation Inflammatory Inflammatory Response Influenza Influenza A virus Interleukin 2 Receptor Interleukin-2 Intervention Knowledge Lung Lymphocyte Lymphoid Cell Memory Modeling Mus Natural Killer Cells Oseltamivir Outcome Pathway interactions Plasma Cells Population Public Health Regulation Regulatory T-Lymphocyte Reporting Role Shapes Signal Transduction Structure of germinal center of lymph node T-Lymphocyte Therapeutic Therapeutic Intervention Tissues Treatment outcome Vaccination Viral Respiratory Tract Infection Virus Virus Diseases antiviral immunity base cytokine release syndrome effector T cell global health immunopathology improved improved outcome influenza infection innovation inorganic phosphate insight memory CD4 T lymphocyte mortality risk novel pre-clinical prevent pulmonary function respiratory infection virus response tissue repair ventilation

项目摘要

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.

甲型流感病毒（IAV）仍然是一个全球性的健康问题，尽管每年的疫苗接种工作。临床干预能够预防与严重IAV感染相关的免疫病理学和“细胞因子风暴”，需要，特别是可以在感染后期启动的方法。知识来自于拟议的研究将促进开发基于IL-2的治疗方法的新应用，治疗严重的呼吸道病毒感染，以及推进其作为佐剂的潜在用途，接种疫苗后的IAV特异性免疫。